Press Releases Moberg Pharma AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 16:29:42 13/05/2024 BST			5-day change	1st Jan Change
27.86 ^SEK	-11.56%		-28.42%	+83.29%

05-07	Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-06	Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure	CI

Moberg Pharma - Positive momentum	05-08	AQ
Moberg Pharma's interim report January - March 2024	05-07	AQ
National approval for MOB-015 in all 13 countries	05-06	AQ
Moberg Pharma : Launch update for MOB-015	04-23	PU
Moberg Pharma : Launch update for MOB-015	04-23	PU
Notice of Annual General Meeting in Moberg Pharma AB (publ)	04-12	AQ
Moberg Pharma Annual report for 2023	04-12	AQ
Moberg Pharma : Corporate Governance Report 2023	04-12	PU
Moberg Pharma : Application submitted to include an additional terbinafine supplier	04-08	PU
The Nomination Committee's proposal to the Annual General Meeting 2024	02-19	AQ
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	02-07	AQ
Moberg Pharma's Interim report January - September 2023	11-07	AQ
Moberg Pharma strengthens the organization	11-07	AQ
Moberg Pharma's Nomination Committee appointed	17/10/23	AQ
MOBERG PHARMA HAS COMPLETED ENROLLMENT TO THE PHASE 3 STUDY FOR MOB-015 IN NORTH AMERICA	09/10/23	AQ
Bulletin from Moberg Pharma's Extraordinary General Meeting	09/10/23	AQ
Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America	06/10/23	AQ
New number of shares and votes in Moberg Pharma AB (publ)	29/09/23	AQ
Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)	13/09/23	AQ
Clarification regarding directed issue of units to guarantors in connection with the completed rights issue	13/09/23	AQ

No results for this search